Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that causes widespread inflammation. It can affect the skin, joints, blood vessels, and multiple organ systems. The exact cause ...

SLE: Systemic lupus erythematosus. Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life.

A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20% of patients and associated factors include younger age, prednisone treatment, ...

A majority of patients with systemic lupus erythematosus achieve prolonged remission when treated with hydroxychloroquine at ...

Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...